Check Presentation

Impact of Giving

History of Giving

Vanderbilt-Ingram has a rich history of giving that helped establish the Cancer Center. Philanthropic gifts may also kick-start early-career scientists' initial research, establish lab spaces for discovery, or aid patient support initiatives.

Ways to Give
A group of doctors and nurses smile while holding Suburu-branded care packages.

The Ingram Family

In 1999, the family of the late E. Bronson Ingram pledged a transformational gift to name the Vanderbilt-Ingram Cancer Center, and Orrin H. Ingram II led a successful fundraising campaign to advance the fight against cancer. However, the Ingrams' support of the Vanderbilt-Ingram Cancer Center began before our recognition as an NCI-designated cancer center and before this transformative gift. Some of that support included the establishment of the Hortense B. Ingram Professorship of Molecular Oncology in honor of E. Bronson Ingram’s mother, who died of cancer, and the funding of recruitment of key faculty and several innovative pilot cancer research projects. After his father's death, Orrin H. Ingram II became actively involved with the Vanderbilt-Ingram Cancer Center's Board of Advisors. Before taking the helm as the board's chairman in November of 1999, he chaired its development committee, established a program to raise private donations for "discovery grants" to fund innovative new research, and launched a series of educational lunch programs to promote cancer research awareness.

Watch the Legacy of Ingram Giving

The A.B. Hancock Jr. Memorial Laboratory for Cancer Research

When Waddell Walker Hancock founded the A.B. Hancock Jr. Memorial Laboratory for Cancer Research in 1972, she was determined that the right combination of imagination, perseverance, and scientific talent could win the fight against cancer.

Black and white photo of the Hancock family.

Hancock Lab researchers have earned many national honors and 23 patents for their studies of the role of inflammation in the progression of cancer and as a target for prevention and early detection. The initial impact was on colon cancer but very recent projects focus on prostate cancer and pancreatic cancer.

Evolving from the foundational work of the Hancock lab, the Vanderbilt-Ingram Cancer Center and the Vanderbilt Institute of Chemical Biology have earned national acclaim for translational research that moves discovery from the lab to benefit patients at the bedside. Today Vanderbilt-Ingram discoveries in cancer genetics are saving lives through precision cancer medicine that precisely targets therapy based on tumor characteristics for patients with melanoma and cancers of the lung, colon, and breast.

More potent cancer medicines are on the horizon as Vanderbilt-Ingram researchers identify promising candidates by designing novel molecules that effectively inhibit notoriously “undruggable” mutations found commonly in many cancers and drug-resistant tumors. This research could ultimately lead to treatment for many different types of cancer.

These groundbreaking innovations testify to the wonderful impact achieved by a remarkable family and friends working closely with Vanderbilt scientists. Their collective determination is offering cancer patients a brighter hope for the future.

Watch a Video about the Hancock Lab

The Robert J. Kleberg, Jr. and Helen C. Kleberg Foundation Center for Personalized Cancer Medicine

For nearly two decades, the generous support from the Robert J. Kleberg, Jr. and Helen C. Kleberg Foundation has played a pivotal role in Vanderbilt-Ingram Cancer Center's ability to impact cancer discovery.

Due to a long-term investment in basic and translational cancer science, support from the Robert J. Kleberg, Jr. and Helen C. Kleberg Foundation has enabled Vanderbilt to emerge as an international leader in the early detection of cancer and precision cancer medicine — matching the right therapy to the right patient at the right time.

Programs in molecular imaging and genomics-based medicine have led to novel findings and more effective therapies for treating patients with head and neck cancers, leukemia, brain tumors, lung cancer, melanoma, and a host of other cancer types.

Moreover, this partnership has served as a catalyst for additional funding from extramural sources that extend the scope and impact of our work.

The support from the Robert J. Kleberg, Jr. and Helen C. Kleberg Foundation serves as a key ingredient in our mission to prevent, control, and cure cancer and to have the greatest possible impact on the health and well-being of cancer patients and their families.

Francis Williams Preston Lab

The T.J. Martell Foundation became an important partner to the Vanderbilt-Ingram Cancer Center in 1993, when the Martell Foundation established the Frances Williams Preston Laboratories. These “laboratories without walls” were created in honor of Frances Preston — the late music industry icon and former president of the Martell Foundation's board — and served as an important cornerstone in the creation of the then-new Vanderbilt Cancer Center.

Since that time, this marriage of music and medicine has led to important discoveries in the fight against cancer and built an important foundation for even greater advances in the years ahead. We have remained true to our commitment to deploy the resources provided by the Martell Foundation in ways that will have the greatest impact. We’re exploring the most innovative frontiers of cancer research, from nascent research in genetic approaches in the labs’ early days to our current focus on proteomics and early detection and prevention.

Picture of Frances Williams Preston, a blonde woman wearing a necklace.

Directed by Dr. Harold L. Moses, the founding director of our cancer center, the Preston Laboratories include the work of 20 senior scientists with active funding from the National Institutes of Health, the U.S. Department of Defense, and the pharmaceutical industry.

The impact of T.J. Martell Foundation is not only felt throughout our cancer center, but also across the country and around the world through MyCancerGenome (opens in a new tab). We look forward to future discoveries for better treatments, earlier detection, and cancer prevention.

Vanderbilt Ingram Cancer Center 2220 Pierce Exterior
$20 million
investment
Hundreds of millions
of dollars in grants
From the National Cancer Institute and other agencies
20+
senior scientists
Research supported

Amy Baker Lab

Amy Baker was a media executive, entrepreneur, and advocate whose famously open arms (and open door) made her home a nexus point connecting thought leaders from across the worlds of media, politics, and philanthropy. She was a dedicated supporter of breast cancer research at Vanderbilt Health, along with her family.

She showed an early interest in media, anchoring the local cable television system when she was only a high school student. She graduated from American University, where she studied communications and played on the tennis team. While in college, she began her 20-year career with NBC in Washington D.C., before eventually relocating to Los Angeles, where she held various management positions, including Director of Program Production and Preparation.

In 1994, she married the love of her life, Barry Baker. As much as Amy relished her success in the media industry, her favorite job was raising her three children — Brandace, Bryce, and Lane — with whom she moved and made her home in Park City, Utah.

Community was of paramount importance to Amy, as demonstrated by her sustained involvement and recognition. She served on numerous boards dedicated to the arts, health, and education throughout her life, including at Temple Har Shalom, Image Reborn, and Rowland Hall, in the local area. Amy co-owned and built Jupiter Bowl, envisioning bringing families and friends of all ages together. Over the years, she opened her home to thousands of Utah residents to engage with powerbrokers and cultural influencers from across the worlds of politics and entertainment.

Three awards commemorate her generosity. First, Amy received the Temple Har Shalom Habonim Award in recognition of her continued devotion and contribution as a community builder. Second, she was the recipient of the first Image Reborn Celebration of Life Award. Lastly, Amy’s generosity and service inspired the People’s Health Clinic to create the Amy Baker Lifetime of Giving Award to forever commemorate people who emulate her purpose. While battling cancer for 16 years, she continued to find a friend in everyone she met. Amy lived her life intending to make the world a better place for her having been in it, and she did so with unending grace.

Honor Amy Baker’s Legacy

To make a gift to advance innovative breast cancer research in Amy’s honor and help further the Baker family’s legacy of making a meaningful difference for those facing the life-changing effects of cancer, please Give Now.

Ambassador Discovery Grants by the Numbers

>$1.5
Million
Funds raised by the Ambassadors for grants and awards
>$45
Million
In funding from the National Cancer Institute and other external resources as a result of Ambassador grants and awards
100's
Publications
Resulted from the seed funding from Ambassador grants and awards

Ambassador Discovery Grants

The Vanderbilt-Ingram Ambassadors program was a volunteer group of young professionals who raised money to award grants for high-risk, high-reward cancer research to promising investigators. This group raised more than $1.5 million for grants through personal contribution, events, and peer-to-peer fundraising. Ambassador investments led to more than $45 million in funding from the National Cancer Institute and other external funding sources, as well as hundreds of publications.

Stacey Huppert, PhD

Targeting Notch Signaling with Small Molecules

Ryoma (Puck) Ohi, PhD

On the Hunt for the Achilles’ Heel of Mitotic Human Cancer Cells

Christopher Chad Quarles, MD

Early Detection of Glioma Treatment Response Using MRI-Based Biomarkers

Christopher S. Williams, MD, PhD

BVES Interacting Proteins in Cancer

Jonathan Irish, PhD

Activating Anti-Tumor Immunity in Combination with Targeted Therapy

Rebecca Ihrie, PhD

Spatial Patterning and Tumor Development in the Brain

Melissa Skala, PhD

Optical metabolic imaging of treatment response in cancer

Ken Lau, PhD

Unraveling the cellular heterogeneity of solid tumors

Carlos Lopez, PhD

A Modeling Framework to Explain and Predict Cell-Death Signal Processing in Cancer

Bryan Venters, PhD

Gene Regulatory Pathways in Human Leukemia

Christine Lovly, MD, PhD

Small Cell Lung Cancer-Innovative Approaches to Study a Recalcitrant Cancer

Jason MacGurn, PhD

Harnessing Protein Degradation to Fight Cancer

Patrick Grohar, MD, PhD

Targeting the “Undruggable” for the Treatment of Pediatric Sarcoma

Javid Moslehi, MD

Induced pluripotent stem cells (iPSC) as a screening platform to assess cardiotoxicity with novel cancer therapies

Manuel Ascano, PhD

Development of Next-generation Cancer Immunotherapeutics: Targeted delivery of a novel small molecule and enhancement of the immune system

Justin Balko, PharmD, PhD

Non-invasive imaging (PET-scanning) of T-cells in tumors: toward a biopsy-less biomarker for response to immunotherapies

Raymond Blind, PhD

Finding Drugs to Inhibit NR5A

John A. Capra, PhD

Personalized Structural Biology to Guide Cancer Treatment

John Karijolich, PhD

The enemy within: Regulating the expression of mutagenic DNA

Jacob Houghton, PhD

Releasing the brakes on the immune system to enhance personalized treatment of pancreatic cancer

Jonathan Brown, MD

Cancer and heart disease: Shared disease mechanisms involving growth and inflammation

Doug Johnson, MD*/Javid Moslehi, MD

Personalized/Precision Medicine in Immuno-Oncology

John Wilson, PhD

STINGing Cancer with Nanoparticles to Enhance Immunotherapy

Kim Sandler, MD/Travis Osterman, DO

Saving Lives with Early Detection of Lung Cancer

Rachelle Johnson, PhD

Targeting dormant tumor cells to prevent recurrence

John Wilson, PhD

Engineering Smart Technologies for Cancer Immunotherapy

P. Brent Ferrell, Jr., MD

Using single cell sequencing to dissect the clonal evolution of leukemia

Satya Das, MD, MSCI

How do we make something good, better? Improving upon the activity of peptide receptor radionuclide therapy (PRRT) in patients with neuroendocrine tumors (NETs)

Alexander Bick, MD, PhD

Building a Time Machine to Intercept Cancer

Kathy DelGiorno, PhD

New Diagnostics for a Deadly Cancer

Michael Topf, MD

Investigating the use of 3D Scanning of Head and Neck Surgical Pathology Specimens

Vivian Weiss, MD, PhD

Understanding the Molecular and Immunologic Mechanisms of Thyroid Cancer Invasion and Metastasis

John Scheel, MD, PhD, MPH

Using Geographic Information Systems to Direct Cancer Care Services

Hillary Tindle, PhD

Development of a Nose-to-Brain (N2B) GLP-1 Receptor Agonist for Cancer-Related Addictions